245 related articles for article (PubMed ID: 32059745)
21. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma.
Chen J; Jin R; Zhao J; Liu J; Ying H; Yan H; Zhou S; Liang Y; Huang D; Liang X; Yu H; Lin H; Cai X
Cancer Lett; 2015 Oct; 367(1):1-11. PubMed ID: 26170167
[TBL] [Abstract][Full Text] [Related]
22. The role of CD29-ILK-Akt signaling-mediated epithelial-mesenchymal transition of liver epithelial cells and chemoresistance and radioresistance in hepatocellular carcinoma cells.
Jiang X; Wang J; Zhang K; Tang S; Ren C; Chen Y
Med Oncol; 2015 May; 32(5):141. PubMed ID: 25805567
[TBL] [Abstract][Full Text] [Related]
23. Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI-110) in Hepatocellular Carcinoma.
Liu M; Zhang L; Li H; Hinoue T; Zhou W; Ohtani H; El-Khoueiry A; Daniels J; O'Connell C; Dorff TB; Lu Q; Weisenberger DJ; Liang G
Hepatology; 2018 Oct; 68(4):1412-1428. PubMed ID: 29774579
[TBL] [Abstract][Full Text] [Related]
24. KDM4B-mediated epigenetic silencing of miRNA-615-5p augments RAB24 to facilitate malignancy of hepatoma cells.
Chen Z; Wang X; Liu R; Chen L; Yi J; Qi B; Shuang Z; Liu M; Li X; Li S; Tang H
Oncotarget; 2017 Mar; 8(11):17712-17725. PubMed ID: 27487123
[TBL] [Abstract][Full Text] [Related]
25. MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2.
Liao H; Bai Y; Qiu S; Zheng L; Huang L; Liu T; Wang X; Liu Y; Xu N; Yan X; Guo H
Oncotarget; 2015 Apr; 6(11):8914-28. PubMed ID: 25871397
[TBL] [Abstract][Full Text] [Related]
26. TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma.
Lai HH; Li CW; Hong CC; Sun HY; Chiu CF; Ou DL; Chen PS
Mol Oncol; 2019 Apr; 13(4):928-945. PubMed ID: 30657254
[TBL] [Abstract][Full Text] [Related]
27. MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.
Kitamura K; Seike M; Okano T; Matsuda K; Miyanaga A; Mizutani H; Noro R; Minegishi Y; Kubota K; Gemma A
Mol Cancer Ther; 2014 Feb; 13(2):444-53. PubMed ID: 24258346
[TBL] [Abstract][Full Text] [Related]
28. Methylation of Ras association domain family protein 1, isoform A correlated with proliferation and drug resistance in hepatocellular carcinoma cell line SMMC-7721.
Zhao QZ; Dou KF
J Gastroenterol Hepatol; 2007 May; 22(5):683-9. PubMed ID: 17444856
[TBL] [Abstract][Full Text] [Related]
29. Differentiation Therapy by Epigenetic Reconditioning Exerts Antitumor Effects on Liver Cancer Cells.
Gailhouste L; Liew LC; Yasukawa K; Hatada I; Tanaka Y; Nakagama H; Ochiya T
Mol Ther; 2018 Jul; 26(7):1840-1854. PubMed ID: 29759938
[TBL] [Abstract][Full Text] [Related]
30. miR-300 regulates the epithelial-mesenchymal transition and invasion of hepatocellular carcinoma by targeting the FAK/PI3K/AKT signaling pathway.
Wang R; Yu Z; Chen F; Xu H; Shen S; Chen W; Chen L; Su Q; Zhang L; Bi J; Zeng W; Li W; Huang X; Wang Q
Biomed Pharmacother; 2018 Jul; 103():1632-1642. PubMed ID: 29864952
[TBL] [Abstract][Full Text] [Related]
31. Serum response factor induces epithelial to mesenchymal transition with resistance to sorafenib in hepatocellular carcinoma.
Bae JS; Noh SJ; Kim KM; Jang KY; Chung MJ; Kim DG; Moon WS
Int J Oncol; 2014 Jan; 44(1):129-36. PubMed ID: 24173109
[TBL] [Abstract][Full Text] [Related]
32. Multifaceted Roles of DNA Methylation in Neoplastic Transformation, from Tumor Suppressors to EMT and Metastasis.
Casalino L; Verde P
Genes (Basel); 2020 Aug; 11(8):. PubMed ID: 32806509
[TBL] [Abstract][Full Text] [Related]
33. Long non-coding RNA CASC2 suppresses epithelial-mesenchymal transition of hepatocellular carcinoma cells through CASC2/miR-367/FBXW7 axis.
Wang Y; Liu Z; Yao B; Li Q; Wang L; Wang C; Dou C; Xu M; Liu Q; Tu K
Mol Cancer; 2017 Jul; 16(1):123. PubMed ID: 28716020
[TBL] [Abstract][Full Text] [Related]
34. Treatment with a new benzimidazole derivative bearing a pyrrolidine side chain overcomes sorafenib resistance in hepatocellular carcinoma.
Suk FM; Liu CL; Hsu MH; Chuang YT; Wang JP; Liao YJ
Sci Rep; 2019 Nov; 9(1):17259. PubMed ID: 31754201
[TBL] [Abstract][Full Text] [Related]
35. The Rho GTPase Rnd1 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma and is a favorable anti-metastasis target.
Qin CD; Ma DN; Zhang SZ; Zhang N; Ren ZG; Zhu XD; Jia QA; Chai ZT; Wang CH; Sun HC; Tang ZY
Cell Death Dis; 2018 May; 9(5):486. PubMed ID: 29706627
[TBL] [Abstract][Full Text] [Related]
36. BMP4 promotes oxaliplatin resistance by an induction of epithelial-mesenchymal transition via MEK1/ERK/ELK1 signaling in hepatocellular carcinoma.
Ma J; Zeng S; Zhang Y; Deng G; Qu Y; Guo C; Yin L; Han Y; Cai C; Li Y; Wang G; Bonkovsky HL; Shen H
Cancer Lett; 2017 Dec; 411():117-129. PubMed ID: 28987388
[TBL] [Abstract][Full Text] [Related]
37. Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents.
Jia H; Yang Q; Wang T; Cao Y; Jiang QY; Ma HD; Sun HW; Hou MX; Yang YP; Feng F
Biochim Biophys Acta; 2016 Jul; 1860(7):1417-30. PubMed ID: 27091611
[TBL] [Abstract][Full Text] [Related]
38. Paracrine Induction of Epithelial-Mesenchymal Transition Between Colorectal Cancer Cells and its Suppression by a p53/miR-192/215/NID1 Axis.
Rokavec M; Bouznad N; Hermeking H
Cell Mol Gastroenterol Hepatol; 2019; 7(4):783-802. PubMed ID: 30831320
[TBL] [Abstract][Full Text] [Related]
39. LncRNA FOXD2-AS1 as a competitive endogenous RNA against miR-150-5p reverses resistance to sorafenib in hepatocellular carcinoma.
Sui C; Dong Z; Yang C; Zhang M; Dai B; Geng L; Lu J; Yang J; Xu M
J Cell Mol Med; 2019 Sep; 23(9):6024-6033. PubMed ID: 31210410
[TBL] [Abstract][Full Text] [Related]
40. Doxycycline as an inhibitor of the epithelial-to-mesenchymal transition and vasculogenic mimicry in hepatocellular carcinoma.
Meng J; Sun B; Zhao X; Zhang D; Zhao X; Gu Q; Dong X; Zhao N; Liu P; Liu Y
Mol Cancer Ther; 2014 Dec; 13(12):3107-22. PubMed ID: 25277383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
